Literature DB >> 7666925

In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.

M A Pfaller1, A L Barry.   

Abstract

A comparative evaluation of the in vitro susceptibilities of 597 clinical yeast isolates to amphotericin B, fluconazole, and 5-fluorocytosine (5FC) was conducted. The broth macrodilution reference method of the National Committee for Clinical Laboratory Standards (NCCLS, M27-P) was adapted to the microdilution method. Microdilution endpoints for amphotericin B were scored as the lowest concentration in which a score of 0 (complete absence of growth) was observed and for 5FC and fluconazole as the lowest concentration in which a score of 2 (prominent decrease in turbidity; MIC-2) was observed compared to the growth control. The MIC values were read after 24 and 48 h incubation. A broad range of MIC values was observed with each antifungal agent. Amphotericin B was very active (MIC90 < or = 1.0 microgram/ml) against all of the yeast isolates with the exception of C. lusitaniae (MIC90 > or = 2.0 micrograms/ml). Fluconazole was most active against C. parapsilosis (MIC90 of 1.0 microgram/ml) and least active against C. krusei (MIC90 of 32 micrograms/ml). 5FC was most active against C. albicans, C. parapsilosis, C. tropicalis, and T. glabrata (MIC90 < or = 1.0 microgram/ml) and was least active against C. krusei and C. lusitaniae (MIC90 > or = 16 micrograms/ml). These data indicate that the microdilution method, performed in accordance with M27-P, provides a means of testing larger numbers of yeast isolates against an array of antifungal agents and allows this to be accomplished in a reproducible and standardized manner. Given these results, it appears that the microdilution method may be a useful alternative to the macrodilution reference method for susceptibility testing of yeasts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666925     DOI: 10.1007/bf01104343

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  26 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Standardized susceptibility testing of fluconazole: an international collaborative study.

Authors:  M A Pfaller; B Dupont; G S Kobayashi; J Müller; M G Rinaldi; A Espinel-Ingroff; S Shadomy; P F Troke; T J Walsh; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 3.  Antifungal susceptibility testing. Current state of technology, limitations, and standardization.

Authors:  M A Pfaller; M G Rinaldi
Journal:  Infect Dis Clin North Am       Date:  1993-06       Impact factor: 5.982

4.  Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.

Authors:  M A Pfaller; C Grant; V Morthland; J Rhine-Chalberg
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 5.  Mycoses caused by Candida lusitaniae.

Authors:  T L Hadfield; M B Smith; R E Winn; M G Rinaldi; C Guerra
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

6.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B.

Authors:  D L Calhoun; G D Roberts; J N Galgiani; J E Bennett; D S Feingold; J Jorgensen; G S Kobayashi; S Shadomy
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

Review 8.  Impact of the changing epidemiology of fungal infections in the 1990s.

Authors:  M Pfaller; R Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

9.  Amphotericin B-resistant yeast infection in severely immunocompromised patients.

Authors:  W G Powderly; G S Kobayashi; G P Herzig; G Medoff
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

10.  Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.

Authors:  M A Pfaller; R N Jones; J A Washington; F P Koontz; E H Gerlach; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

View more
  8 in total

1.  Typing of Candida glabrata in clinical isolates by comparative sequence analysis of the cytochrome c oxidase subunit 2 gene distinguishes two clusters of strains associated with geographical sequence polymorphisms.

Authors:  G F Sanson; M R Briones
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  A quantitative bioassay for extracellular metabolites that antagonize growth of filamentous fungi, and its use with biocontrol fungi.

Authors:  S Mischke
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

3.  Strain variation among and antifungal susceptibilities of isolates of Candida krusei.

Authors:  Y F Berrouane; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

4.  Fluconazole disk diffusion procedure for determining susceptibility of Candida species.

Authors:  A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

5.  In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  J N Galgiani; M L Lewis
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Fatty acid synthase impacts the pathobiology of Candida parapsilosis in vitro and during mammalian infection.

Authors:  Long Nam Nguyen; David Trofa; Joshua D Nosanchuk
Journal:  PLoS One       Date:  2009-12-22       Impact factor: 3.240

7.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

8.  Fluconazole disk diffusion susceptibility testing of Candida species.

Authors:  W R Kirkpatrick; T M Turner; A W Fothergill; D I McCarthy; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.